EDITORIAL
1248 Propensity methods for multiple sclerosis: The devil is in the details
D Ontaneda and TE Love

TOPICAL REVIEW
1250 Sedentary behaviour in people with multiple sclerosis: Is it time to stand up against MS?
Jet JCSV van Zanten, LA Pilutti, JL Duda and RW Motl

CONTROVERSIES IN MULTIPLE SCLEROSIS
1258 Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – YES
M Freedman and HL Atkins
1260 Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – NO
PS Sorensen
1263 Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – Commentary
EM Mowry

ORIGINAL RESEARCH PAPERS
1266 Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease
K Weier, V Fonov, B Aubert-Broche, L Arnold, B Banwell and DL Collins
1279 High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis
MD Steenwijk, H Vrenken, LE Jonkman, et al.
1289 Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions
N Mistry, R Abdel-Fahim, A Samaraweera, et al.
1297 Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
L Kappos, N De Stefano, MS Freedman, et al.
1306 Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis
LE Jonkman, L Fleyscher, MD Steenwijk, et al.
1315 Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
D Baroncini, A Ghezzi, PO Annovazzi, et al.
1327 Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients
N Bergslund, R Zivadinov, MG Dwyer, B Weinstock-Guttman and RHB Benedict
1337 Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica
R Yamasaki, T Matsushita, T Fukazawa, et al.
1349 A comparative analysis of Patient-Reported Expanded Disability Status Scale tools
CDE Collins, B Ivy, JD Bowen, EM Cheng, et al.
1359 Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis
A Conte, P Li Voti, S Pontecorvo, et al.

SHORT REPORTS
1367 Optimal detection of infratentorial lesions with a combined dual-echo MRI sequence: “PT2”
MI Gaitán, P Yahes, P Sati, C Romero, DS Reich and J Correale
1371 Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria
A Uzawa, M Mori, T Uchida, H Masuda, R Ohtani and S Kuwabara

Cover image adapted from Figure 1, in the article, Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients, by Niels Bergslund, Robert Zivadinov, Michael G Dwyer, Bianca Weinstock-Guttman and Ralph HB Benedict, page 1331.

Affiliated with the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), the Latin American Committee on Treatment and Research of Multiple Sclerosis (LACTRIMS) and Rehabilitation in Multiple Sclerosis (RIMS). MSJ is the official journal of the European Charcot Foundation.